Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Core Insights - Natera, Inc. has launched EDEN, a large multi-center prospective study to evaluate its non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications [1] Group 1: Company Overview - Natera, Inc. is a global leader in cell-free DNA and precision medicine [1] Group 2: Industry Context - Preeclampsia affects approximately 5-8% of pregnancies and is a leading cause of maternal and neonatal morbidity [1]